LiverLearning®: 2021 Portal Hypertension: Clinical and Experimental SIG: Controversies in the Screening and Prevention of Clinically Significant Portal Hypertension

This program combines didactic lectures and lively debate to examine controversies in the screening and prevention of clinically significant portal hypertension. Talks cover groundbreaking advances in basic, translational, outcomes, and clinical research in portal hypertension that may be incorporated into clinical practice, along with new pharmacologic interventions to prevent disease progression in these patients.

LiverLearning®: 2021 Leon Schiff State-of-the-Art Lecture: Tiny Yet Powerful—Microbes and Their Potential for Treatment of Liver Diseases

Complex multi-directional interactions occur between the gut microbiota and the liver. A disturbance of this delicate homeostasis can contribute to liver disease. Effects of untargeted microbiota therapies including antibiotics, probiotics and fecal microbiota transplantation, have been assessed in clinical trials.  Precision and targeted modifications such as engineered bacteria, postbiotics and phages, can precisely edit the microbiota and modify liver disease progression.

The Impact of Median Model for End‐Stage Liver Disease at Transplant Minus 3 National Policy on Waitlist Outcomes in Patients With and Without Hepatocellular Carcinoma

Sarah Bernards, Ryutaro Hirose, Francis Y. Yao, Chengshi Jin, Jennifer L. Dodge, Chiung‐Yu Huang, Neil Mehta – 10 November 2021 – As a result of ongoing regional disparities, the United Network for Organ Sharing (UNOS) implemented policy in May 2019 limiting exception points for waitlisted patients with hepatocellular carcinoma (HCC) to median Model for End‐Stage Liver Disease at transplant in the area surrounding a transplant center minus 3 points (MMAT‐3). The impact of this policy change remains unknown.

Noninvasive Risk Stratification for Nonalcoholic Fatty Liver Disease Among Living Liver Donor Candidates: A Proposed Algorithm

Nilay Danis, Sharon R. Weeks, Ahyoung Kim, Azarakhsh Baghdadi, Maryam Ghadimi, Ihab R. Kamel, Behnam Saberi, Tinsay Woreta, Jacqueline Garonzik‐Wang, Benjamin Philosophe, Ahmet Gurakar, Rohit Loomba – 8 November 2021 – To reduce waitlist mortality, living donor liver transplantation (LDLT) has increased over the past decade in the United States, but not at a rate sufficient to completely mitigate organ shortage. As a result, there are ongoing efforts to expand the living liver donor pool.

Subscribe to